Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage

British Journal of Haematology

Volumn 129, Issue 2, 2005, Pages 189-198

  Palle, Josefine ^a   Frost, B M ^a   Forestier, E ^b   Gustafsson, G ^c   Nygren, P ^d   Hellebostad, M ^e   Jonsson, O G ^f   Kanerva, J ^g   Schmiegelow, K ^h   Larsson, R ^d   Lonnerholm G ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h Rigshospitalet   (Denmark)

Author keywords

Acute leukaemia; Childhood; Chromosomal rearrangements; Drug sensitivity; Mixed lineage leukaemia

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMSACRINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 11; CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; FLUOROMETRY; GENE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LEUKOCYTE COUNT; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MLL GENE; NEWBORN; PRIORITY JOURNAL;

EID: 20244380336     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05433.x     Document Type: Article

References (37)

1. Armstrong, S.A., Staunton, J.E., Silverman, LB., Pieters, R., den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R. & Korsmeyer, S.J. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics, 30, 41-47.
2. Behm, F.G., Raimondi, S.C., Frestedt, J.L., Liu, Q., Crist, W.M., Downing, J.R., Rivera, G.K., Kersey, J.H. & Pui, C.H. (1996) Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood, 87, 2870-2877.
3. Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van't Veer, M.B. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 9, 1783-1786.
4. Ferrando, A.A., Armstrong, S.A., Neuberg, D.S., Sallan, S.E., Silverman, L.B., Korsmeyer, S.J. & Look, A.T. (2003) Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood, 102, 262-268.
5. Forestier, E., Johansson, B., Borgstrom, G., Kerndrup, G., Johansson, J. & Heim, S. (2000) Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leukemia Cytogenetic Study Group. European Journal of Haematology, 64, 194-200.
6. Forestier, E., Heim, S., Blennow, E., Borgstrom, G., Holmgren, G., Heinonen, K., Johannsson, J., Kerndrup, G., Andersen, M.K., Lundin, C., Nordgren, A., Rosenquist, R., Swolin, B. & Johansson, B. (2033) Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. British Journal of Haematology, 121, 566-577.
7. Fridborg, H., Jonsson, E., Nygren, P. & Larsson, R. (1999) Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. European Journal of Cancer, 35, 424-432.
8. Frost, B.M., Nygren, P., Gustafsson, G., Forestier, E., Jonsson, O.G., Kanerva, J., Nygaard, R., Schmiegelow, K., Larsson, R. & Lonnerholm, G. (2003) Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. British Journal of Haematology, 122, 376-385.
9. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
10. Gustafsson, G., Schmiegelow, K., Forestier, E., Clausen, N., Glomstein, A., Jonmundsson, G., Mellander, L., Makipernaa, A., Nygaard, R. & Saarinen-Pihkala, U.M. (2000) Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia, 14, 2267-2275.
11. Hughes, J.M., de Fazio, A. & Tattersall, M.H. (1988) Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay. British Journal of Cancer, 57, 459-463.
12. Kaaijk, P., Kaspers, G.J., Van Wering, E.R., Broekema, G.J., Loonen, A.H., Hahlen, K., Schmiegelow, K., Janka-Schaub, G.E., Henze, G., Creutzig, U. & Veerman, A.J. (2003) Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. British Journal of Cancer, 88, 775-781.
13. Kaspers, G.J. & Veerman, A.J. (2003) Clinical significance of cellular drug resistance in childhood leukemia. Recent Results in Cancer Research, 161, 196-220.
14. Kaspers, G.J., Pieters, R., Van Zantwijk, C.H., De Laat, P.A., De Waal, F.C., Van Wering, E.R. & Veerman, A.J. (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. British Journal of Cancer, 64, 469-474.
15. Kaspers, G.J., Kardos, G., Pieters, R., Van Zantwijk, C.H., Klumper, E., Hahlen, K., de Waal, F.C., van Wering, E.R. & Veerman, A.J. (1994) Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia, 8, 1224-1229.
16. Kaspers, G.J., Veerman, A.J., Pieters, R., Van Zantwijk, C.H., Smets, L.A., Van Wering, E.R. & Van Der Does-Van Den Berg, A. (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood, 90, 2723-2729.
17. Larsson, R. (1997) Prediction of cytotoxic drug resistance in acute leukemia. In: Drug Resistance in Oncology, Vol. 1 (ed. by S. Bernal), pp. 249-278. Dekker Marcel, New York, USA.
18. Larsson, R. & Nygren, P. (1993) Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. European Journal of Cancer, 29A, 1208-1212.
19. Larsson, R., Kristensen, J., Sandberg, C. & Nygren, P. (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). International Journal of Cancer, 50, 177-185.
20. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L. & Gustafsson, G. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 122, 217-225.
21. Mitelman, F. (ed.) (1995) An International System for Human Cytogenetic Nomenclature. Karger S, Basel, Switzerland.
22. Mitelman, F. (2005) Database of Chromosome Aberrations in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman (last accessed February, 2005)
23. Nygren, P., Kristensen, J., Jonsson, B., Sundstrom, C., Lonnerholm, G., Kreuger, A. & Larsson, R. (1992) Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia, 6, 1121-1128.
24. Nygren, P., Fridborg, H., Csoka, K., Sundstrom, C., de la Torre, M., Kristensen, J., Bergh, J., Hagberg, H., Glimelius, B., Rastad, J. Tholander, B. & Larsson R. (1994) Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 56, 715-720.
25. Pieters, R., Huismans, D.R., Leyva, A. & Veerman, A.J. (1988) Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Letters, 41, 323-332.
26. Preisler, H.D., Azarnia, N. & Marinello, M. (1984) Relationship of the growth of leukemic cells in vitro to the outcome of therapy for acute nonlymphocytic leukemia. Cancer Research, 44, 1712-1717.
27. Pui, C.H., Raimondi, S.C., Srivastava, D.K., Tong, X., Behm, F.G., Razzouk, B., Rubnitz, J.E., Sandlund, J.T., Evans, W.E. & Ribeiro, R. (2000) Prognostic factors in infants with acute myeloid leukemia. Leukemia, 14, 684-687.
28. Pui, C.H., Gaynon, P.S., Boyett, J.M., Chessells, J.M., Baruchel, A., Kamps, W., Silverman, L.B., Biondi, A., Harms, D.O., Vilmer, E., Schrappe, M. & Camitta, B. (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet, 359, 1909-1915.
29. Pui, C.H., Chessells, J.M., Camitta, B., Baruchel, A., Biondi, A., Boyett, J.M., Carroll, A., Eden, O.B., Evans, W.E., Gadner, H., Harbott, J., Harms, D.O., Harrison, C.J., Harrison, P.L., Heerema, N., Janka-Schaub, G., Kamps, W., Masera, G., Pullen, J., Raimondi, S.C., Richards, S., Riehm, H., Sallan, S., Sather, H., Shuster, J., Silverman, L.B., Valsecchi, M.G., Vilmer, E., Zhou, Y., Gaynon, P.S. & Schrappe, M. (2003) Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia, 17, 700-706.
30. Raimondi, S.C., Chang, M.N., Ravindranath, Y., Behm, F.G., Gresik, M.V., Steuber, C.P., Weinstein, H.J. & Carroll, A.J. (1999) Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood, 94, 3707-3716.
31. Ramakers-van Woerden, N.L., Beverloo, H.B., Veerman, A.J., Camitta, B.M., Loonen, A.H., van Wering, E.R., Slater, R.M., Harbott, J., den Boer, M.L., Ludwig, W.D., Haas, O.A., Janka-Schaub, G.E. & Pieters, R. (2004) In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia, 18, 521-529.
32. Ross, M.E., Mahfouz, R., Onciu, M., Liu, H.C, Zhou, X., Song, G., Shurtleff, S.A., Pounds, S., Cheng, C., Ma, J., Ribeiro, R.C., Rubnitz, J.E., Girtman, K., Williams, W.K., Raimondi, S.C., Liang, D.C., Shih, L.Y., Pui, CH. & Downing, J.R. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 104, 3679-3687.
33. Rubnitz, J.E. & Pui, C.H. (2003) Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treatment Reviews, 29, 31-44.
34. Rubnitz, J.E., Raimondi, S.C., Tong, X., Srivastava, D.K., Razzouk, B.I., Shurtleff, S.A., Downing, J.R., Pui, C.H., Ribeiro, R.C. & Behm, F.G. (2002) Favorable impact of the t(9;11) in childhood acute myeloid leukemia. Journal of Clinical Oncology, 20, 2302-2309.
35. Tannock, I. (1987) The Basic Science of Oncology. Pergamon press, New York, USA.
36. Zwaan, C.M., Kaspers, G.J., Pieters, R., Ramakers-Van Woerden, N.L., den Boer, M.L., Wunsche, R., Rottier, M.M., Hahlen, K., van Wering, E.R., Janka-Schaub, G.E., Creutzig, U. & Veerman, A.J. (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 96, 2879-2886.
37. Zwaan, C.M., Kaspers, G.J., Pieters, R., Hahlen, K., Huismans, D.R., Zimmermann, M., Harbott, J., Slater, R.M., Creutzig, U. & Veerman, A.J. (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 100, 3352-3360.